Novel compounds selective antagonists of NK-3, pharmaceutical composition and methods for use in disorders mediated by receptors NK3

A compound of formula I: ** ** Formula and pharmaceutically acceptable salts and solvates thereof, wherein Ar1 is a 5- or aryl group to 6-membered cycloalkyl group having 3 to 6-membered heterocyclyl group of 3 to 6 members or a C3-C6 alkyl group, each of the aryl, heteroaryl, cycloalkyl or heterocyclyl optionally substituted with one or more groups selected from halo, cyano, alkyl, haloalkyl, cycloalkyl, heteroalkyl, heterocyclyl, aryl, aralkyl, heteroaryl , hydroxyl, alkoxy, haloalkoxy, alkoxyalkoxy, alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino, carbamoyl, alkylcarbamoyl, carbamoylamino, alquilcarbamoilamino, alkylsulfonyl, haloalkylsulfonyl, sulfamoyl, alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, or two substituents form an alkylenedioxy group or haloalquilenodioxi group, or two substituents form a cycloalkyl or structural undad heterocycloalkyl together with the cycloalkyl or heterocycloalkyl group to which they are attached or fused to aryl heterocycloalkyl, heteroaryl, cycloalkyl or may be one or more structural unit aryl, each of said substituents optionally substituted with one or more additional substituents selected from halo , cyano, alkyl, haloalkyl, cyclopropyl, alkoxy, haloalkoxy, heterocyclyl, aryl, heteroaryl, aryloxy, heteroaryloxy; L1 is carbonyl; R1 is H, a C1-C4 alkyl, aryl or aralkyl, each of said alkyl, aryl or aralkyl optionally substituted by one or more groups selected from halo or hydroxy; R1 'is H or a C1-C4 alkyl group; R2 is H or C1-C4 alkyl group; R2 'is H or a C1-C4 alkyl group; R3 is H or C1-C4 alkyl group optionally substituted by hydroxy; R3 'is H or a C1-C4 alkyl group; X1 and X2 are N; L2 is a single bond or carbonyl, Ar2 is a 5- to 6-membered aryl group or, each of the aryl groups or heteroaryl optionally substituted by one or more groups selected from halo, cyano, alkyl, hydroxyalkyl, haloalkyl, cycloalkyl , heteroalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, hydroxy, alkoxy, haloalkoxy, alkylamino, carboxy, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonylamino, haloalkylcarbonylamino, acylamino, carbamoyl, alkylcarbamoyl, carbamoyl, carbamoylamino, alquilcarbamoilamino, alkylsulfonyl, haloalkylsulfonyl, arylsulfonylalkyl, sulfamoyl , alkylsulfamoyl, alkylsulfonylamino, haloalkylsulfonylamino, or two substituents form an alkylenedioxy group or haloalquilenodioxi group, or fused to aryl or heteroaryl group may be one or more structural units cycloalkyl, aryl, heterocyclyl or heteroaryl, each of said substituents optionally spare parts uid with one or more additional substituents selected from halo, cyano, alkyl, haloalkyl, alkoxy, haloalkoxy, cycloalkyl, heterocyclyl optionally substituted by alkyl, aryl, heteroaryl, hydroxy, alkoxyalkyl, hydroxyalkoxy, alkylamino, alkylsulfonylamino, alkoxycarbonylamino, alkylamino, or alcoxicarbonilaminoalcoxi; and wherein when R1, R1 ', R2, R2', R3, R3 'are H, and L2 is single bond, and Ar 1 is a 6-membered aryl optionally substituted by one or more groups selected from halo, cyano, C1-C3 alkyl, C1 haloalkyl, and Ar2 is a 5- aryl or 6-membered optionally substituted by one or more groups selected from halo, C1-C3 alkyl, hydroxyl, methoxy, or fused to an aryl or heteroaryl group optionally substituted by one or more halo, C1-C3 alkyl, hydroxyl, methoxy additional then Ar 1 is phenyl, 3-halophenyl, 4-halophenyl, 2,3-dichlorophenyl, 2,4-difluorophenyl, 2,5-dihalophenyl, 2 , 6- difluorophenyl, 2,6- dichlorophenyl, 3,4-dihalophenyl, 3,5-dihalophenyl, 3,4,5-trihalophenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 2,3- dicyanophenyl, 2 , 4-dicyanophenyl, 3,5-dicyanophenyl, 3-cyano-4-halophenyl, 4- (C1-C3 alkyl) phenyl, 3,4-di (C1-C3 alkyl) phenyl, 3,5-di (C1- C3 alkyl) phenyl, 4- (C1 haloalkyl) phenyl, and Ar2 is 2- (C1-C3 alkyl) thiazol-4-yl, 5- (C1-C3 lquil) thiazol-4-yl, pyridin-2-yl, 4-halopiridin-2-yl, 4- (C1-C3 alkyl) pyridin-2-yl, 5- pyridin-2-yl (C1-C3 alkyl), 6- (C1-C3 alkyl) pyridin-2-yl, quinolin-2-yl, isoquinolin-3-yl, 8- haloquinolin-2-yl, benzothiazol-2-yl, 4,5,6,7-tetrahydro- yl-1,3-benzothiazol-2; with the following conditions: - Ar1 is neither a pyrazolo [1,5-a] pyridin-2-yl substituted or unsubstituted not a estructutal unit pyrazolo [1,5-a] pyrimidine-2-yl substituted or unsubstituted; and the compound of formula I is not one of: (2,4-difluorophenyl) (3- (pyridin-2-yl) -5,6-dihydro- [1,2,4] triazolo [4,3-a] pyrazin-7 (8H) -yl) methanone; (3-chlorophenyl) (3- (pyridin-2-yl) -5,6-dihydro- [1,2,4] triazolo [4,3-a] pyrazin-7 (8H) -yl) methanone; 2- (3- (pyridin-2-yl) -5,6,7,8-tetrahydro- [1,2,4] triazolo [4,3-a] pyrazine-7-carbonyl) benzonitrile; (2,6-dichlorophenyl) (3- (pyridin-2-yl) -5,6-dihydro- [1,2,4] triazolo [4,3-a] pyrazin-7 (8H) -yl) methanone, (2,3-dichlorophenyl) (3- (pyridin-2-yl) -5,6-dihydro- [1,2,4] triazolo [4,3-a] pyrazin-7 (8H) -yl) methanone, (2,3-dichlorophenyl) (3- (5-methylpyridin-2-yl) -5,6-dihydro- [1,2,4] triazolo [4,3-a] pyrazin-7 (8H) -yl) methanone, (2,3-dichlorophenyl) (3- (6-methylpyridin-2-yl) -5,6-dihydro- [1,2,4] triazolo [4,3-a] pyrazin-7 (8H) - yl) methanone.